An Open-label Phase 1b/2 Study of Binimetinib Administered in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 10 Oct 2018
At a glance
- Drugs Binimetinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Array BioPharma
- 28 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 28 Sep 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Jun 2019.
- 20 Jan 2018 Trial design presented at the 2018 Gastrointestinal Cancers Symposium